Cargando…

Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying COPD detection

BACKGROUND: During the treatment phase of active pulmonary tuberculosis (PTB), respiratory function impairment is usually restrictive. This may become obstructive, as a PTB-associated airflow obstruction (AFO) or as a later manifestation of underlying COPD. PURPOSE: The aim of the study was to exami...

Descripción completa

Detalles Bibliográficos
Autores principales: Radovic, Milan, Ristic, Lidija, Ciric, Zorica, Dinic-Radovic, Violeta, Stankovic, Ivana, Pejcic, Tatjana, Rancic, Milan, Bogdanovic, Dragan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914072/
https://www.ncbi.nlm.nih.gov/pubmed/27366058
http://dx.doi.org/10.2147/COPD.S106875
_version_ 1782438503784644608
author Radovic, Milan
Ristic, Lidija
Ciric, Zorica
Dinic-Radovic, Violeta
Stankovic, Ivana
Pejcic, Tatjana
Rancic, Milan
Bogdanovic, Dragan
author_facet Radovic, Milan
Ristic, Lidija
Ciric, Zorica
Dinic-Radovic, Violeta
Stankovic, Ivana
Pejcic, Tatjana
Rancic, Milan
Bogdanovic, Dragan
author_sort Radovic, Milan
collection PubMed
description BACKGROUND: During the treatment phase of active pulmonary tuberculosis (PTB), respiratory function impairment is usually restrictive. This may become obstructive, as a PTB-associated airflow obstruction (AFO) or as a later manifestation of underlying COPD. PURPOSE: The aim of the study was to examine the potential causes and risks for AFO development in PTB by exploring the aspects of spirometry limitations and clinical implications for the underlying COPD detection, taking into account various confounding factors. PATIENTS AND METHODS: Prospective, nest case–control study on 40 new cases of PTB with initial restrictive respiratory function impairment, diagnosed and treated according to the directly observed treatment short course (DOTS) strategy. RESULTS: From all observed patients, 37.5% of them developed AFO upon the completion of PTB treatment, with significantly increased average of forced vital capacity (%) (P<0.01). Their changes in forced expiratory volume in the first second (%) during the PTB treatment were strongly associated with the air pollution exposure in living (0.474%–20.971% for 95% confidence interval [CI]; P=0.041) and working environments (3.928%–20.379% for 95% CI; P=0.005), initial radiological extent of PTB lesions (0.018%–0.700% for 95% CI; P=0.047), leukocyte count (0.020%–1.328% for 95% CI; P=0.043), and C-reactive protein serum level (0.046%–0.205% for 95% CI; P=0.003) compared to the other patients. The multivariate logistic regression analysis model shows initial radiological extent of pulmonary tuberculosis lesions (OR 1.01–1.05 for 95% CI; P=0.02) and sputum conversion rate on culture (OR 1.02–1.68 for 95% CI; P=0.04) as the most significant predictors for the risk of AFO development. CONCLUSION: AFO upon PTB treatment is a common manifestation of underlying COPD, which mostly occurs later, during the reparative processes in active PTB, even in the absence of major risk factors, such as cigarette smoking and biomass fuel dust exposure. Initial spirometry testing in patients with active PTB is not a sufficient and accurate approach in the detection of underlying COPD, which may lead to their further potential health deterioration.
format Online
Article
Text
id pubmed-4914072
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49140722016-06-30 Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying COPD detection Radovic, Milan Ristic, Lidija Ciric, Zorica Dinic-Radovic, Violeta Stankovic, Ivana Pejcic, Tatjana Rancic, Milan Bogdanovic, Dragan Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: During the treatment phase of active pulmonary tuberculosis (PTB), respiratory function impairment is usually restrictive. This may become obstructive, as a PTB-associated airflow obstruction (AFO) or as a later manifestation of underlying COPD. PURPOSE: The aim of the study was to examine the potential causes and risks for AFO development in PTB by exploring the aspects of spirometry limitations and clinical implications for the underlying COPD detection, taking into account various confounding factors. PATIENTS AND METHODS: Prospective, nest case–control study on 40 new cases of PTB with initial restrictive respiratory function impairment, diagnosed and treated according to the directly observed treatment short course (DOTS) strategy. RESULTS: From all observed patients, 37.5% of them developed AFO upon the completion of PTB treatment, with significantly increased average of forced vital capacity (%) (P<0.01). Their changes in forced expiratory volume in the first second (%) during the PTB treatment were strongly associated with the air pollution exposure in living (0.474%–20.971% for 95% confidence interval [CI]; P=0.041) and working environments (3.928%–20.379% for 95% CI; P=0.005), initial radiological extent of PTB lesions (0.018%–0.700% for 95% CI; P=0.047), leukocyte count (0.020%–1.328% for 95% CI; P=0.043), and C-reactive protein serum level (0.046%–0.205% for 95% CI; P=0.003) compared to the other patients. The multivariate logistic regression analysis model shows initial radiological extent of pulmonary tuberculosis lesions (OR 1.01–1.05 for 95% CI; P=0.02) and sputum conversion rate on culture (OR 1.02–1.68 for 95% CI; P=0.04) as the most significant predictors for the risk of AFO development. CONCLUSION: AFO upon PTB treatment is a common manifestation of underlying COPD, which mostly occurs later, during the reparative processes in active PTB, even in the absence of major risk factors, such as cigarette smoking and biomass fuel dust exposure. Initial spirometry testing in patients with active PTB is not a sufficient and accurate approach in the detection of underlying COPD, which may lead to their further potential health deterioration. Dove Medical Press 2016-06-16 /pmc/articles/PMC4914072/ /pubmed/27366058 http://dx.doi.org/10.2147/COPD.S106875 Text en © 2016 Radovic et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Radovic, Milan
Ristic, Lidija
Ciric, Zorica
Dinic-Radovic, Violeta
Stankovic, Ivana
Pejcic, Tatjana
Rancic, Milan
Bogdanovic, Dragan
Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying COPD detection
title Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying COPD detection
title_full Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying COPD detection
title_fullStr Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying COPD detection
title_full_unstemmed Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying COPD detection
title_short Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying COPD detection
title_sort changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis – limitations for the underlying copd detection
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914072/
https://www.ncbi.nlm.nih.gov/pubmed/27366058
http://dx.doi.org/10.2147/COPD.S106875
work_keys_str_mv AT radovicmilan changesinrespiratoryfunctionimpairmentfollowingthetreatmentofseverepulmonarytuberculosislimitationsfortheunderlyingcopddetection
AT risticlidija changesinrespiratoryfunctionimpairmentfollowingthetreatmentofseverepulmonarytuberculosislimitationsfortheunderlyingcopddetection
AT ciriczorica changesinrespiratoryfunctionimpairmentfollowingthetreatmentofseverepulmonarytuberculosislimitationsfortheunderlyingcopddetection
AT dinicradovicvioleta changesinrespiratoryfunctionimpairmentfollowingthetreatmentofseverepulmonarytuberculosislimitationsfortheunderlyingcopddetection
AT stankovicivana changesinrespiratoryfunctionimpairmentfollowingthetreatmentofseverepulmonarytuberculosislimitationsfortheunderlyingcopddetection
AT pejcictatjana changesinrespiratoryfunctionimpairmentfollowingthetreatmentofseverepulmonarytuberculosislimitationsfortheunderlyingcopddetection
AT rancicmilan changesinrespiratoryfunctionimpairmentfollowingthetreatmentofseverepulmonarytuberculosislimitationsfortheunderlyingcopddetection
AT bogdanovicdragan changesinrespiratoryfunctionimpairmentfollowingthetreatmentofseverepulmonarytuberculosislimitationsfortheunderlyingcopddetection